# RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

> **NCT03675893** · PHASE2 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 180 (estimated)

## Conditions studied

- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Abemaciclib
- **DRUG:** LY3023414
- **DRUG:** Metformin
- **DRUG:** Zotatifin
- **DRUG:** Gedatolisib

## Key facts

- **NCT ID:** NCT03675893
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-12-24
- **Primary completion:** 2028-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675893, "RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03675893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*